Upadacitinib Is a Better Choice than Abrocitinib for Patients with Moderate-to-Severe Atopic Dermatitis: An Updated Meta-Analysis

Figure 3

Forest plot of EASI-75 responder (“events” means amount of EASI-75 responder).